S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
Log in
NASDAQ:CMRX

Chimerix Stock Forecast, Price & News

$9.28
-0.06 (-0.64 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.91
Now: $9.28
$9.59
50-Day Range
$3.62
MA: $5.92
$9.34
52-Week Range
$1.19
Now: $9.28
$10.72
Volume963,737 shs
Average Volume2.77 million shs
Market Capitalization$581.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Chimerix logo

MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

618th out of 1,922 stocks

Pharmaceutical Preparations Industry

316th out of 769 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074
Employees43

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.52 million
Book Value$1.79 per share

Profitability

Net Income$-112,580,000.00
Net Margins-321.31%

Miscellaneous

Market Cap$581.24 million
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$9.28
-0.06 (-0.64 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chimerix (NASDAQ:CMRX) Frequently Asked Questions

How has Chimerix's stock been impacted by COVID-19 (Coronavirus)?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CMRX shares have increased by 544.4% and is now trading at $9.28.
View which stocks have been most impacted by COVID-19
.

Is Chimerix a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chimerix stock.
View analyst ratings for Chimerix
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Chimerix?

Wall Street analysts have given Chimerix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chimerix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Chimerix
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biopharmaceutical company earned $1.61 million during the quarter, compared to analyst estimates of $1.40 million. Chimerix had a negative net margin of 321.31% and a negative trailing twelve-month return on equity of 36.57%.
View Chimerix's earnings history
.

What price target have analysts set for CMRX?

2 equities research analysts have issued 1 year price targets for Chimerix's stock. Their forecasts range from $10.00 to $16.00. On average, they expect Chimerix's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 40.1% from the stock's current price.
View analysts' price targets for Chimerix
or view Wall Street analyst' top-rated stocks.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Mr. Michael A. Sherman, CEO, Pres & Director (Age 55, Pay $869.4k)
  • Mr. Michael T. Andriole M.B.A., Chief Bus. Officer, Sec. & CFO (Age 48, Pay $539.79k)
  • Dr. Michael A. Alrutz, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51, Pay $619.5k)
  • Mr. David Jakeman, Exec. Director of Fin. & Accounting and Principal Accounting Officer (Age 44)
  • Dr. Roy W. Ware, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier, Chief Science Officer
  • Ms. Michelle LaSpaluto, VP of Strategic Planning & Investor Relations
  • Dr. Allen S. Melemed M.B.A., M.D., Chief Medical Officer

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $9.28.

How big of a company is Chimerix?

Chimerix has a market capitalization of $581.24 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 43 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is www.chimerix.com.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.